《罗沙司他治疗肾性贫血中国专家共识》解读

Interpretation of the expert consensus on the treatment for renal anemia with Roxadustat in China

肾性贫血是慢性肾脏病患者常见且重要的并发症,近年来肾性贫血治疗取得重要进展。作为机制全新的新一代肾性贫血治疗药物,全球首个低氧诱导因子脯氨酰羟化酶抑制剂——罗沙司他(Roxadustat)在中国首先上市使用,国内外众多证据已表明,它能显著改善肾性贫血患者血红蛋白水平,成为该病临床治疗的新选择。为及时总结罗沙司他临床应用进展,更好地指导该药在临床的合理应用,中国研究型医院学会肾脏病学专业委员会编写《罗沙司他治疗肾性贫血中国专家共识》,文章对该共识进行扼要解读。

Renal anemia is one of the most common and important complications in patients with chronic kidney disease. In recent years,great progression has been made in the treatment of renal anemia. As a new generation of anti-anemia drug with new mechanism,Roxadostat,the first hypoxia-inducible factor prolyl hydroxylase inhibitor worldwide,was firstly approved for marketing in China. A lot of evidence has proved that Roxadostat can significantly improve the hemoglobin level in patients with renal anemia,thus becoming a novel strategy for the clinical treatment of the disease. The Nephrology Committee of Chinese Research Hospital Association issued the“Expert consensus on the treatment for renal anemia with Roxadustat in China”,which aims to summarize its current clinical application of Roxadustat in China in order to better guide its prational use in clinical practice. This article will briefly introduce the main content of this consensus.